LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Home・Aktien・Amgen Inc

Amgen Inc

Geschlossen

BrancheGesundheitswesen

326.2 -3.03

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

325.13

Max

336.3

Schlüsselkennzahlen
By Trading Economics
Einkommen	486M 1.8B
Verkäufe	-1.3B 8.6B
KGV Branchendurchschnitt	22.936 51.415
EPS	5.15
Dividendenrendite	2.91
Gewinnspanne	21.107
Angestellte	31,500
EBITDA	-2.3B 2.7B

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+8.47% upside

Dividenden
By Dow Jones
Dividendenrendite Branchendurchschnitt	2.91% 2.34%
Nächstes Ergebnis	4. Aug. 2026
Nächste Dividendenausschüttung	5. Juni 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-5.4B 178B
Vorheriger Eröffnungskurs	329.23
Vorheriger Schlusskurs	326.2

Nachrichtenstimmung

By Acuity

32%

68%

81 / 345 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

270.44 / 276.44 Unterstützung & Widerstand

Amgen Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

Amgen Inc Prognose

Kursziel

By TipRanks

8.47% Vorteil

12-Monats-Prognose

Durchschnitt 364.7 USD 8.47%

Hoch 427 USD

Tief 300 USD

Basierend auf 24 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Amgen Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

24 ratings

Buy

Halten

Sell

Basierend auf 24 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Amgen Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

270.44 / 276.44Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

Stimmung

By Acuity

81 / 345 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.